On 22 January 2025, Samsung Biologics revealed its Q4 and 2024 annual financial results, reporting full year 2024 consolidated revenue of over 4 trillion won (approx. USD2.78bn), a 23% increase compared to 2023. According to the Korea Herald, this makes Samsung Biologics the first biotech company in South Korea to reach this sales milestone.
Samsung Biologics’ Q2/24 consolidated revenue was KRW 1.26 trillion, with operating profit of KRW 325.7 billion.
Samsung Biologic’s biosimilar subsidiary, Samsung Bioepis, achieved 2024 consolidated revenue of 1.537 trillion won, a 51% increase year on year. Its operating profit more than doubled compared to 2024, at 435 billion won.
Biosimilar highlights for 2024 are reported to include the European launch (July 2024) and US FDA approval (July 2024) of SB17/Pyzchiva® (ustekinumab, biosimilar to J&J/Janssen’s Stelara®), the US approval (July 2024) of SB12/Epysqli™ (eculizumab, biosimilar to Alexion’s Soliris®), the European (November 2024) and US FDA approval (May 2024) of SB15/Opuviz® (aflibercept, biosimilar to Regeneron’s Eylea®), and the positive CHMP opinion (November 2024) for SB16/Obodence®/Xbryk® (denosumab, biosimilar to Amgen’s Prolia® and Xgeva®).